Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal anti...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705202/
https://ncbi.nlm.nih.gov/pubmed/22149875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113216
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料